allogeneic b-lymphocytes
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT02007811)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Aplastic · Phase 1/Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Multiple Myeloma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- B-cellsSupplementation
B-cells supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- allogeneic b-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02007811 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2013 | German Research Foundation, Julius-Maximilians University, University of Duisburg-Essen, University of Erlangen-Nuremberg, University of Regensburg |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| German Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Julius-Maximilians University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Duisburg-Essen | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Regensburg | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1